Asthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators), By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers), By Route of Administration (Oral, Inhaled, Others), By Region and Competition, 2019-2029F
Published Date: November - 2024 | Publisher: MIR | No of Pages: 320 | Industry: Healthcare | Format: Report available in PDF / Excel Format
View Details Buy Now 2890 Download Sample Ask for Discount Request CustomizationAsthma Therapeutics Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class (Anti-inflammatory, Combination Therapy, Bronchodilators), By Product (Inhalers (Dry powder inhalers, Metered dose inhalers, Soft mist inhalers), Nebulizers), By Route of Administration (Oral, Inhaled, Others), By Region and Competition, 2019-2029F
| Forecast Period | 2025-2029 |
| Market Size (2023) | USD 23.52 Billion |
| CAGR (2024-2029) | 3.25% |
| Fastest Growing Segment | Combination Therapy |
| Largest Market | North America |
Market Size (2029) | USD 28.38 Billion |
Market Overview
Global Asthma Therapeutics Market
Inhaled corticosteroids, leukotriene modifiers, and long-acting beta-agonists are among the commonly prescribed medications for asthma management. These medications help alleviate symptoms and prevent exacerbations by targeting underlying inflammation and bronchial constriction. Additionally, short-acting beta-agonists such as albuterol are often used for immediate symptom relief during acute asthma attacks, providing rapid bronchodilation to improve airflow and alleviate symptoms. The global asthma therapeutics market is poised for further evolution and improvement in asthma management. Innovations in drug development, including the introduction of new biologics and other novel therapies, hold promise for providing additional treatment options for patients with severe and uncontrolled asthma. Biologics, in particular, target specific pathways involved in asthma pathogenesis, offering personalized treatment approaches tailored to individual patient needs. These advancements in treatment modalities have the potential to revolutionize asthma management, offering better outcomes and improved quality of life for patients.
Ongoing research into the genetic and molecular basis of asthma is expected to drive personalized treatment strategies and enhance our understanding of the disease. By identifying genetic markers and molecular pathways associated with asthma susceptibility and severity, researchers aim to develop targeted therapies that address the underlying mechanisms driving the disease. Personalized treatment plans based on genetic profiling and biomarker analysis could enable healthcare providers to tailor therapies to individual patient profiles, optimizing treatment outcomes and minimizing adverse effects. The global asthma therapeutics market continues to evolve in response to the growing burden of asthma worldwide. Advances in medical research, drug development, and personalized medicine offer new hope for patients with asthma, providing a range of treatment options and improving overall asthma management. By leveraging innovative therapies and personalized treatment approaches, healthcare providers can better meet the needs of patients with asthma, reducing symptom burden, preventing exacerbations, and improving quality of life.
Key Market Drivers
Rising Prevalence of Asthma
Asthma is a global health concern, affecting people of all ages, from children to the elderly. The burden of asthma is not just limited to its prevalence but extends to its impact on patients' lives and healthcare costs
Sedentary lifestyles, changes in dietary habits, and increased stress levels have been linked to the rising prevalence of asthma. These factors can lead to obesity, which is a known risk factor for asthma.
Increasing Healthcare Expenditure
Asthma is a chronic respiratory condition that affects millions of people worldwide. With a rising prevalence of asthma and an increasing focus on healthcare, the global asthma therapeutics market is experiencing significant growth. One of the primary drivers of this growth is the increasing healthcare expenditure in various countries.
In many countries, the accessibility of asthma medications has improved significantly due to increased healthcare expenditure. This means that patients have better access to a wide range of asthma therapeutics, from quick-relief inhalers to long-term control medications. This improved access ensures that patients can manage their condition effectively, leading to better health outcomes.
Research and development in the asthma therapeutics market are heavily influenced by healthcare expenditure. Greater financial support for research activities results in the discovery of new drugs and therapies that can revolutionize asthma management. These advancements benefit both patients and the pharmaceutical industry, as they create a more competitive and dynamic market.
While increasing healthcare expenditure is driving growth in the asthma therapeutics market, there are some challenges to address. Balancing the need for better treatments with the rising cost of healthcare is a delicate task. It's essential to ensure that healthcare resources are utilized efficiently and that affordable treatment options are found at to all, regardless of socioeconomic status.
Key Market Challenges
Generic Competition
The patent expirations of several blockbuster asthma drugs have led to increased competition from generic alternatives. While this can drive down prices, it can also pose a challenge for pharmaceutical companies and innovators in terms of sustaining profitability and investing in research and development for new, innovative therapies.
Key Market Trends
Technological Advancements
Asthma is a chronic respiratory condition that affects millions of people worldwide, causing symptoms such as wheezing, shortness of breath, and coughing. With the increasing prevalence of asthma cases globally, the demand for effective and innovative asthma therapeutics is on the rise. Technological advancements have played a pivotal role in the development of new and improved treatments, leading to a booming Global Asthma Therapeutics Market
Advancements in genetic research and personalized medicine have allowed for the development of targeted asthma treatments. By identifying specific genetic markers associated with asthma, pharmaceutical companies can create therapies tailored to an individual's unique genetic profile. This approach leads to more effective treatments and fewer side effects.
AI and machine learning are invaluable tools in asthma research. They analyze vast amounts of patient data, identify patterns, and predict asthma exacerbations. Researchers use AI to develop predictive models that can guide treatment decisions and improve patient outcomes.
Segmental Insights
Drug Class Insights
Based on
Product Insights
Based on product, the inhalers is projected to experience rapid growth in the global asthma therapeutics market during the forecast period.
Regional Insights
Based on region, North America emerged as the dominant region in the Global Asthma Therapeutics Market in 2023, holding the largest market share in terms of value. One of the primary reasons for North America's leading position in the global asthma therapeutics market is the high prevalence of asthma in the region. The United States, Canada, and Mexico collectively have a substantial population suffering from asthma, which drives the demand for effective asthma treatments and medications. As a result, pharmaceutical companies are heavily invested in the North American market, leading to a robust pipeline of asthma therapeutics.
Recent Developments
- In April 2024, Teva Pharmaceutical Industries Ltd. and Launch Therapeutics, Inc., unveiled a clinical collaboration agreement aimed at expediting the clinical research program for Teva's ICS-SABA (TEV-'248). Additionally, Teva, in partnership with Abingworth, a prominent international life sciences investment group under global investment firm Carlyle (NASDAQCG), announced a strategic development funding agreement. Under this agreement, Abingworth is set to provide Teva with up to USD 150 million to help cover the costs associated with Teva's ICS/SABA (TEV-'248) program.
Key Market Players
- Teva Pharmaceutical Industries Ltd.
- GSK plc.
- Merck & Co.,Inc.
- F. Hoffmann-LaRoche Ltd.
- AstraZeneca plc.
- BoehringerIngelheim International GmbH
- Sanofi S.A.
- KoninklijkePhilips N.V.
- Becton,Dickinson and Company
- SunovionPharmaceuticals, Inc.
|
By Drug Class |
By Product | By Route of Administration |
By Region |
|
|
|
|
FAQ'S
For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:
Within 24 to 48 hrs.
You can contact Sales team (sales@marketinsightsresearch.com) and they will direct you on email
You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.
Discounts are available.
Hard Copy